Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs

Cellular Signalling

Volumn 25, Issue 11, 2013, Pages 2115-2124

  Ueda, Fumihito ^a   Sumi, Kazuya ^a   Tago, Kenji ^b   Kasahara, Tadashi ^a   Funakoshi Tago, Megumi ^a  

^a KEIO UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

CDDP; FANCC; JAK2; MMC; Myeloproliferative neoplasm; V617F mutation

Indexed keywords

BLEOMYCIN; CISPLATIN; DNA; FANCONI ANEMIA GROUP A PROTEIN; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP E PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; FANCONI ANEMIA GROUP L PROTEIN; JANUS KINASE 2; MITOMYCIN; STAT5 PROTEIN;

ANIMAL CELL; ARTICLE; CELL TRANSFORMATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; GENE SILENCING; MOUSE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UBIQUITINATION; WILD TYPE;

ATAXIA-TELANGIECTASIA MUTATED; ATM; CDDP; EPO; EPOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; ESSENTIAL THROMBOCYTHEMIA; ET; FA; FANCC; FANCONI ANEMIA; JAK2; JANUS KINASE 2; MMC; MPNS; MYELOPROLIFERATIVE NEOPLASM; MYELOPROLIFERATIVE NEOPLASMS; PMF; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PV; REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION; RT-PCR; SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTION 5; STAT5; TAE; TBE; TRIS-ACETIC ACID-EDTA; TRIS-BORIC ACID-EDTA; V617F MUTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BLEOMYCIN; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP C PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; JANUS KINASE 2; MICE; MITOMYCIN; MUTATION; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 84881007320     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2013.07.003     Document Type: Article

References (31)

1. Ihle J.N., Kerr I.M. Trends Genet. 1995, 11:69-74.
2. Ihle J.N., Gilliland D.G. Curr. Opin. Genet. Dev. 2007, 17:8-14.
3. Jatiani S.S., Baker S.J., Silverman L.R., Reddy E.P. Genes Cancer 2010, 1:979-993.
4. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., Garçon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., Vainchenker W. Nature 2005, 434:1144-1148.
5. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Fröhling S., Döhner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J., Gilliland D.G. Cancer Cell 2005, 7:387-397.
6. Funakoshi-Tago M., Pelletier S., Moritake H., Parganas E., Ihle J.N. Mol. Cell. Biol. 2008, 28:1792-1801.
7. Abe M., Funakoshi-Tago M., Tago K., Kamishimoto J., Aizu-Yokota E., Sonoda Y., Kasahara T. Int. Immunopharmacol. 2009, 9:870-877.
8. Sumi K., Tago K., Kasahara T., Funakoshi-Tago M. FEBS Lett. 2011, 23:1884-1890.
9. Chin H., Nakamura N., Kamiyama R., Miyasaka N., Ihle J.N., Miura O. Blood 1996, 88:4415-4425.
10. Quelle F.W., Wang D., Nosaka T., Thierfelder W.E., Stravopodis D., Weinstein Y., Ihle J.N. Mol. Cell. Biol. 1996, 16:1622-1631.
11. Um M., Lodish H.F. J. Biol. Chem. 2006, 281:5648-5656.
12. Funakoshi-Tago M., Tago K., Abe M., Sonoda Y., Kasahara T. J. Biol. Chem. 2010, 285:5296-5307.
13. Funakoshi-Tago M., Nagata T., Tago K., Tsukada M., Tanaka K., Nakamura S., Mashino T., Kasahara T. Cell. Signal. 2012, 24:2024-2034.
14. Kamishimoto J., Tago K., Kasahara T., Funakoshi-Tago M. Cell. Signal. 2011, 23:849-856.
15. Funakoshi-Tago M., Sumi K., Kasahara T., Tago K. PLoS One 2013, 8:e52844.
16. Bagby G.C. Curr. Opin. Hematol. 2003, 10:68-76.
17. Kalb R., Neveling K., Nanda I., Schindler D., Hoehn H. Genome Dyn. 2006, 1:218-242.
18. Kitao H., Takata M. Int. J. Hematol. 2011, 93:417-424.
19. Joenje H., Patel K.J. Nat. Rev. Genet. 2001, 2:446-457.
20. Moldovan G.L., D'Andrea A.D. Cell 2009, 139:1222-1224.
21. Liu T., Ghosal G., Yuan J., Chen J., Huang J. Science 2010, 329:693-696.
22. Funakoshi-Tago M., Shimizu T., Tago K., Nakamura M., Itoh H., Sonoda Y., Kasahara T. Biochem. Pharmacol. 2008, 76:662-671.
23. Suzuki H., Nagai K., Yamaki H., Tanaka N., Umezawa H. J Antibiot (Tokyo) 1968, 21:379-386.
24. Byrnes R.W., Petering D.H. Biochem. Pharmacol. 1991, 41:1241-1248.
25. Burma S., Chen B.P., Murphy M., Kurimasa A., Chen D.J. J. Biol. Chem. 2001, 276:42462-42467.
26. Ward I.M., Chen J. J. Biol. Chem. 2001, 276:47759-47762.
27. Pang Q., Christianson T.A., Keeble W., Koretsky T., Bagby G.C. J. Biol. Chem. 2002, 277:49638-49643.
28. Pang Q., Keeble W., Christianson T.A., Faulkner G.R., Bagby G.C. EMBO J. 2001, 20:4478-4789.
29. Cumming R.C., Lightfoot J., Beard K., Youssoufian H., O'Brien P.J., Buchwald M. Nat. Med. 2001, 7:814-820.
30. Palagyi A., Neveling K., Plinninger U., Ziesch A., Targosz B.S., Denk G.U., Ochs S., Rizzani A., Meier D., Thasler W.E., Hanenberg H., De Toni E.N., Bassermann F., Schäfer C., Göke B., Schindler D., Gallmeier E. Mol. Cancer 2010, 9:127.
31. Frenzilli G., Bosco E., Barale R. Mutat. Res. 2000, 468:93-108.